A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Four Different Doses of Org 50081 in the Treatment of Moderate to Severe Vasomotor Symptoms Associated With the Menopause
Latest Information Update: 09 May 2022
At a glance
- Drugs Esmirtazapine (Primary)
- Indications Vasomotor symptoms
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Organon
- 07 Jun 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 07 Jun 2019 This trial has been completed in Finland, according to European Clinical Trials Database.
- 07 Oct 2009 Additional lead trial centre and sponsor (Schering-Plough) identified as reported by ClinicalTrials.gov.